Aadi Bioscience, Inc.
DB:3350 Rapporto sulle azioni
Aadi Bioscience Salute del bilancio
Salute finanziaria criteri di controllo 6/6 Aadi Bioscience ha un patrimonio netto totale di $68.9M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $85.7M e $16.8M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi n/a Contanti US$62.62m Patrimonio netto US$68.87m Totale passività US$16.83m Totale attività US$85.70m
Aggiornamenti recenti sulla salute finanziaria
Mostra tutti gli aggiornamenti
Aadi Bioscience, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31 Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce Aug 23
Aadi Bioscience Provides PRECISION1 Trial Updates Aug 21
Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.67 loss in 2Q 2023) Aug 08
Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 01
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index Jul 03
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting May 24
New minor risk - Profitability May 10
Forecast to breakeven in 2026 May 09
First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023) May 08
Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024 Apr 28
Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022) Mar 14
Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024 Mar 07 Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Feb 13
Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations Dec 15
Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.68 loss in 3Q 2022) Nov 10
New minor risk - Market cap size Oct 19
Aadi Bioscience, Inc. Announces Executive Changes Oct 05
Second quarter 2023 earnings released: US$0.67 loss per share (vs US$0.87 loss in 2Q 2022) Aug 10
Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 03
First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022) May 10
High number of new directors Apr 20
High number of new directors Feb 16
High number of new directors Jan 25
Aadi Bioscience, Inc. Announces Management Changes Nov 29
High number of new directors Nov 21
Third quarter 2022 earnings released: US$0.68 loss per share (vs US$9.17 loss in 3Q 2021) Nov 10 Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023
Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium Oct 13
Now 21% undervalued Oct 01
Second quarter 2022 earnings released: US$0.87 loss per share (vs US$0.22 loss in 2Q 2021) Aug 11
Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022 Aug 11
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index Jun 26
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications Jun 02
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications Jun 01
Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Present at 2022 ASCO Annual Meeting May 27
High number of new directors May 26
First quarter 2022 earnings released: US$0.66 loss per share (vs US$0.71 loss in 1Q 2021) May 13 Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders May 10
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services May 05
High number of new directors Apr 29
Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes Apr 01
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 18
Less than half of directors are independent Mar 01
Aadi Bioscience, Inc. Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa Feb 24
Interim Chief Financial Officer Lance Thibault has left the company Dec 01
Aadi Bioscience, Inc. Announces FDA Approval of Its First Product Fyarro™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) Nov 24
No independent directors Sep 01
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $77.3M ) di 3350 superano le sue passività a breve termine ( $15.8M ).
Passività a lungo termine: Le attività a breve termine di 3350 ( $77.3M ) superano le sue passività a lungo termine ( $1.0M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: 3350 è esente da debiti.
Riduzione del debito: 3350 non aveva debiti 5 anni fa.
Analisi della pista di contanti Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: 3350 ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero .
Previsione Cash Runway: 3350 ha una liquidità sufficiente per 1.1 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 38.2 % ogni anno.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}